Skip to main content
Erschienen in: DNP - Der Neurologe & Psychiater 2/2015

06.02.2015 | Fortbildung

Primärprävention

Risikofaktoren für Schlaganfall und ihre therapeutische Beeinflussung

verfasst von: Dr. med. Burkhard Alber, Robert Müller, Prof. Dr. med. Gerhard F. Hamann

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Primärprävention zielt bei kardiovaskulären Erkrankungen vor allem auf eine Beeinflussung der Risikofaktoren. In der täglichen Praxis wird die Primärprävention seltener ein Grund für einen Besuch beim Neurologen sein, trotzdem sind die grundlegenden Kenntnisse dieses Feldes aufgrund allgemeiner Lebensberatung der Patienten, aber auch wegen der Ähnlichkeit zu bestimmten sekundärpräventiven Eingriffen wichtig.
Literatur
1.
Zurück zum Zitat Goldstein LB, Bushnell CD, Adams RL et al: Guidlines for the Primary Prevention of Stroke: A Guidline for healthcare professionals. Stroke. 2011; 42: 517–584PubMedCrossRef Goldstein LB, Bushnell CD, Adams RL et al: Guidlines for the Primary Prevention of Stroke: A Guidline for healthcare professionals. Stroke. 2011; 42: 517–584PubMedCrossRef
2.
Zurück zum Zitat Schreiber AK, Haberl RL: Risikofaktoren. In: Hamann GF, Siebler M, von Scheidt W: Schlaganfall. ecomed. 2002. Schreiber AK, Haberl RL: Risikofaktoren. In: Hamann GF, Siebler M, von Scheidt W: Schlaganfall. ecomed. 2002.
3.
Zurück zum Zitat Ringelstein EB, Nabavi DG: Der ischämische Schlaganfall. Kohlhammer. 2007.Di Ringelstein EB, Nabavi DG: Der ischämische Schlaganfall. Kohlhammer. 2007.Di
4.
Zurück zum Zitat Dichgans M: Monogene Erkrankungen als Ursache von Schlaganfällen. In: Hamann GF, Siebler M, von Scheidt W: Schlaganfall. ecomed. 2002. Dichgans M: Monogene Erkrankungen als Ursache von Schlaganfällen. In: Hamann GF, Siebler M, von Scheidt W: Schlaganfall. ecomed. 2002.
6.
Zurück zum Zitat D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB: Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994 Jan;25(1):40–3.PubMedCrossRef D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB: Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994 Jan;25(1):40–3.PubMedCrossRef
7.
Zurück zum Zitat Polak JF et al: The Value of Carotid Artery Plaque and Intima-Media Thickness for Incident Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2013; 2:e000087 doi: 10.1161/JAHA.113.000087PubMedCentralPubMedCrossRef Polak JF et al: The Value of Carotid Artery Plaque and Intima-Media Thickness for Incident Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2013; 2:e000087 doi: 10.1161/JAHA.113.000087PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Bots ML, Groenewegen KA, Anderson TJ et al: Common carotid intima-media thickness measurements do not improve cardiovascular risk prediction in individuals with elevated blood pressure: the USE-IMT collaboration. Hypertension. 2014. 63:1173–1181PubMedCrossRef Bots ML, Groenewegen KA, Anderson TJ et al: Common carotid intima-media thickness measurements do not improve cardiovascular risk prediction in individuals with elevated blood pressure: the USE-IMT collaboration. Hypertension. 2014. 63:1173–1181PubMedCrossRef
9.
Zurück zum Zitat Hamann GF: Prädiktoren bei zerebrovaskulären Erkrankungen. Nervenarzt. 2014. 85:1269-1279. Hamann GF: Prädiktoren bei zerebrovaskulären Erkrankungen. Nervenarzt. 2014. 85:1269-1279.
10.
Zurück zum Zitat Ibrahim-Verbaas CA, Fornage M, Bis JC et al (2014) Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. Stroke 45:403–412.PubMedCentralPubMedCrossRef Ibrahim-Verbaas CA, Fornage M, Bis JC et al (2014) Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. Stroke 45:403–412.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Tikk K, Sookthai D, Monni S, Gross ML, Lichy C, Kloss M, Kaaks R: Primary preventive potential for stroke by avoidance of major lifestyle risk factors: the European Prospective Investigation into Cancer and Nutrition-Heidelberg cohort. Stroke2014 Jul;45(7):2041-6. (12) Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52:818-827. Tikk K, Sookthai D, Monni S, Gross ML, Lichy C, Kloss M, Kaaks R: Primary preventive potential for stroke by avoidance of major lifestyle risk factors: the European Prospective Investigation into Cancer and Nutrition-Heidelberg cohort. Stroke2014 Jul;45(7):2041-6. (12) Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52:818-827.
12.
Zurück zum Zitat Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305–313.PubMedCrossRef Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305–313.PubMedCrossRef
13.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.PubMedCrossRef
14.
Zurück zum Zitat Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.PubMedCrossRef Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.PubMedCrossRef
15.
Zurück zum Zitat Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534–2544PubMedCrossRef Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534–2544PubMedCrossRef
16.
Zurück zum Zitat Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–2544.PubMedCrossRef Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–2544.PubMedCrossRef
17.
Zurück zum Zitat Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009:CD001841. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009:CD001841.
18.
Zurück zum Zitat Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014 Oct 28(20) James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20 Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014 Oct 28(20) James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20
19.
Zurück zum Zitat Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–486.PubMedCrossRef Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–486.PubMedCrossRef
20.
Zurück zum Zitat Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318.PubMedCrossRef Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318.PubMedCrossRef
21.
Zurück zum Zitat Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke. 2013 Oct;44(10):2821–8.PubMedCrossRef Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke. 2013 Oct;44(10):2821–8.PubMedCrossRef
22.
Zurück zum Zitat Rodriguez BL, D’Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, Curb JD. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke. 2002;33:230–236.PubMedCrossRef Rodriguez BL, D’Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, Curb JD. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke. 2002;33:230–236.PubMedCrossRef
23.
Zurück zum Zitat Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348:498 -505 Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348:498 -505
24.
Zurück zum Zitat Guide to Clinical Preventive Services: Report of the U. S. Preventive Services Task Force. Baltimore, MD: Williams and Wilkins; 1996. Guide to Clinical Preventive Services: Report of the U. S. Preventive Services Task Force. Baltimore, MD: Williams and Wilkins; 1996.
25.
Zurück zum Zitat Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care. 2008;31:1132–1137.PubMedCrossRef Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care. 2008;31:1132–1137.PubMedCrossRef
26.
Zurück zum Zitat Biessels GJ, Reijmer YD. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes. 2014 Jul;63(7):2244–52.PubMedCrossRef Biessels GJ, Reijmer YD. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes. 2014 Jul;63(7):2244–52.PubMedCrossRef
27.
28.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.PubMedCrossRef Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.PubMedCrossRef
29.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.PubMedCrossRef Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.PubMedCrossRef
30.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.PubMedCrossRef Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.PubMedCrossRef
31.
Zurück zum Zitat Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353: 2643–2653.PubMedCrossRef Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353: 2643–2653.PubMedCrossRef
32.
Zurück zum Zitat Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361–376. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361–376.
33.
Zurück zum Zitat (35) Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. J Cardiovasc Risk. 1999;6:241–249. (35) Tuomilehto J, Rastenyte D. Diabetes and glucose intolerance as risk factors for stroke. J Cardiovasc Risk. 1999;6:241–249.
34.
Zurück zum Zitat (36) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253–259. (36) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253–259.
35.
Zurück zum Zitat Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE)
36.
Zurück zum Zitat study. J Am Coll Cardiol. 2005;45:705–711. study. J Am Coll Cardiol. 2005;45:705–711.
37.
Zurück zum Zitat Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens. 2008;26:2103–2111.PubMedCrossRef Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens. 2008;26:2103–2111.PubMedCrossRef
38.
Zurück zum Zitat Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007; 100:1254–1262.PubMedCrossRef Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007; 100:1254–1262.PubMedCrossRef
39.
Zurück zum Zitat Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.PubMedCrossRef Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.PubMedCrossRef
40.
Zurück zum Zitat Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.PubMedCrossRef Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.PubMedCrossRef
41.
Zurück zum Zitat Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet.
43.
Zurück zum Zitat Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–1226.PubMedCrossRef Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–1226.PubMedCrossRef
44.
Zurück zum Zitat Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.PubMedCrossRef Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.PubMedCrossRef
45.
Zurück zum Zitat ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563–1574.PubMedCrossRef ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563–1574.PubMedCrossRef
46.
Zurück zum Zitat Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904–910.PubMedCrossRef Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904–910.PubMedCrossRef
47.
Zurück zum Zitat Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563–572.PubMedCrossRef Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563–572.PubMedCrossRef
48.
Zurück zum Zitat Cholesterol Treatment Trialists’ (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 17 000 participants in 26 randomised trials Lancet. Nov 13, 2010; 376(9753): 1670–1681.CrossRef Cholesterol Treatment Trialists’ (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 17 000 participants in 26 randomised trials Lancet. Nov 13, 2010; 376(9753): 1670–1681.CrossRef
49.
Zurück zum Zitat Sanossian N, Saver JL, Navab M, Ovbiagele B. High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke. 2007;38: 1104–1109PubMedCrossRef Sanossian N, Saver JL, Navab M, Ovbiagele B. High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke. 2007;38: 1104–1109PubMedCrossRef
50.
Zurück zum Zitat Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889–934.PubMedCrossRef Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889–934.PubMedCrossRef
51.
Zurück zum Zitat Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729–2735.PubMedCrossRef Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729–2735.PubMedCrossRef
52.
Zurück zum Zitat Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke. Stroke. 2003;34: 2930–2934.PubMedCrossRef Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke. Stroke. 2003;34: 2930–2934.PubMedCrossRef
53.
Zurück zum Zitat Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678–2686.PubMedCrossRef Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678–2686.PubMedCrossRef
55.
Zurück zum Zitat Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR. Risk of arterial thrombosis in Relation to Oral Contraceptives (RATIO) Study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–1208.PubMedCrossRef Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR. Risk of arterial thrombosis in Relation to Oral Contraceptives (RATIO) Study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–1208.PubMedCrossRef
56.
Zurück zum Zitat Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, Van der Graaf Y. Prothrombotic conditions, oral contraceptives and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213–1217.PubMedCrossRef Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, Van der Graaf Y. Prothrombotic conditions, oral contraceptives and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213–1217.PubMedCrossRef
57.
Zurück zum Zitat Manson JE1, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013 Oct 2;310(13):1353–68.PubMedCrossRef Manson JE1, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013 Oct 2;310(13):1353–68.PubMedCrossRef
58.
Zurück zum Zitat Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–1124.PubMedCrossRef Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–1124.PubMedCrossRef
59.
Zurück zum Zitat He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006;367:320–326.PubMedCrossRef He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006;367:320–326.PubMedCrossRef
60.
Zurück zum Zitat Bao Y, Han J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Association of nut consumption with total and cause-specific mortality. N Engl J Med. 2013 Nov 21;369(21):2001–11.PubMedCentralPubMedCrossRef Bao Y, Han J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Association of nut consumption with total and cause-specific mortality. N Engl J Med. 2013 Nov 21;369(21):2001–11.PubMedCentralPubMedCrossRef
61.
Zurück zum Zitat Estruch R, Ros E, Salas-Salvadó J et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4;368(14):1279–90.PubMedCrossRef Estruch R, Ros E, Salas-Salvadó J et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4;368(14):1279–90.PubMedCrossRef
62.
64.
Zurück zum Zitat Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003;34:2475–2481.PubMedCrossRef Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003;34:2475–2481.PubMedCrossRef
65.
Zurück zum Zitat Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, Kromhout D. Physical activity and stroke: a meta-analysis of observational data. Int J Epidemiol. 2004;33:787–798.PubMedCrossRef Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, Kromhout D. Physical activity and stroke: a meta-analysis of observational data. Int J Epidemiol. 2004;33:787–798.PubMedCrossRef
66.
Zurück zum Zitat Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141–1147.PubMedCrossRef Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141–1147.PubMedCrossRef
67.
Zurück zum Zitat Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 1996;276:205–210.PubMedCrossRef Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 1996;276:205–210.PubMedCrossRef
68.
Zurück zum Zitat Kokkinos PF, Holland JC, Pittaras AE, Narayan P, Dotson CO, Papademetriou V. Cardiorespiratory fitness and coronary heart disease risk factor association in women. J Am Coll Cardiol. 1995;26:358–364.PubMedCrossRef Kokkinos PF, Holland JC, Pittaras AE, Narayan P, Dotson CO, Papademetriou V. Cardiorespiratory fitness and coronary heart disease risk factor association in women. J Am Coll Cardiol. 1995;26:358–364.PubMedCrossRef
69.
Zurück zum Zitat Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, Chan HT, Tsao CK, Tsai SP, Wu X. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet. 2011 Oct 1;378(9798):1244–53.PubMedCrossRef Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, Chan HT, Tsao CK, Tsai SP, Wu X. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet. 2011 Oct 1;378(9798):1244–53.PubMedCrossRef
70.
Zurück zum Zitat Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373: 1083–1096.PubMedCrossRef Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373: 1083–1096.PubMedCrossRef
71.
Zurück zum Zitat Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34:1586–1592.PubMedCrossRef Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34:1586–1592.PubMedCrossRef
72.
Zurück zum Zitat Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL. Obesity: a stubbornly obvious target for stroke prevention. Stroke. 2013 Jan;44(1):278–86PubMedCrossRef Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL. Obesity: a stubbornly obvious target for stroke prevention. Stroke. 2013 Jan;44(1):278–86PubMedCrossRef
73.
Zurück zum Zitat Marjolein de Weerd, MS et al: Prevalence of Asymptomatic Carotid Artery Stenosis in the General Population. Stroke. 2010;41:1294–1297PubMedCrossRef Marjolein de Weerd, MS et al: Prevalence of Asymptomatic Carotid Artery Stenosis in the General Population. Stroke. 2010;41:1294–1297PubMedCrossRef
75.
Zurück zum Zitat Eckstein HH, Kühnl A et al: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose. 2012. AWMF Registernummer 004/028. Eckstein HH, Kühnl A et al: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose. 2012. AWMF Registernummer 004/028.
76.
Zurück zum Zitat Sillesen H, Amarenco P, Hennerici MG, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39(12):3297–3302.PubMedCrossRef Sillesen H, Amarenco P, Hennerici MG, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39(12):3297–3302.PubMedCrossRef
77.
Zurück zum Zitat The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef
78.
Zurück zum Zitat Calvillo-King L: Predicting Risk of Perioperative Death and Stroke After Carotid Endarterectomy in Asymptomatic Patients: Derivation and Validation of a Clinical Risk Score. Stroke. 2010; 41(12): 2786–2794.PubMedCentralPubMedCrossRef Calvillo-King L: Predicting Risk of Perioperative Death and Stroke After Carotid Endarterectomy in Asymptomatic Patients: Derivation and Validation of a Clinical Risk Score. Stroke. 2010; 41(12): 2786–2794.PubMedCentralPubMedCrossRef
79.
Zurück zum Zitat Conrad MF, Kang J, Mukhopadhyay S, Patel VI, LaMuraglia GM, Cambria RP: A risk prediction model for determining appropriateness of CEA in patients with asymptomatic carotid artery stenosis. Ann Surg. 2013 Oct;258(4):534–8.PubMed Conrad MF, Kang J, Mukhopadhyay S, Patel VI, LaMuraglia GM, Cambria RP: A risk prediction model for determining appropriateness of CEA in patients with asymptomatic carotid artery stenosis. Ann Surg. 2013 Oct;258(4):534–8.PubMed
80.
Zurück zum Zitat Kakkos SK, Nicolaides AN, Charalambous I, et al; Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg. 2014;59(4):956–967.PubMedCrossRef Kakkos SK, Nicolaides AN, Charalambous I, et al; Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg. 2014;59(4):956–967.PubMedCrossRef
81.
Zurück zum Zitat Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA.1995;273:1421–1428.CrossRef Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA.1995;273:1421–1428.CrossRef
82.
Zurück zum Zitat Rothwell PM, Goldstein LB: Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke. 2004;35. 2425–2427.PubMedCrossRef Rothwell PM, Goldstein LB: Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke. 2004;35. 2425–2427.PubMedCrossRef
83.
Zurück zum Zitat Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, Pan H, Peto R, Potter J, Rahimi K, Rau A, Robertson S, Streifler J, Thomas D. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010;376:1074–84.PubMedCentralPubMedCrossRef Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, Pan H, Peto R, Potter J, Rahimi K, Rau A, Robertson S, Streifler J, Thomas D. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010;376:1074–84.PubMedCentralPubMedCrossRef
84.
Zurück zum Zitat Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370–2375.PubMedCrossRef Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370–2375.PubMedCrossRef
85.
Zurück zum Zitat Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J 2006;27:949–953.PubMedCrossRef Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J 2006;27:949–953.PubMedCrossRef
86.
Zurück zum Zitat Olesen JB, Torp-Pedersen C, Hansen ML, Lip G. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107:1172–1179.PubMedCrossRef Olesen JB, Torp-Pedersen C, Hansen ML, Lip G. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107:1172–1179.PubMedCrossRef
87.
Zurück zum Zitat Trappe HJ: Atrial fibrillation: established and innovative methods of evaluation and treatment. Dtsch Arztebl Int. 2012: 109(1–2): 1–7.PubMedCentralPubMed Trappe HJ: Atrial fibrillation: established and innovative methods of evaluation and treatment. Dtsch Arztebl Int. 2012: 109(1–2): 1–7.PubMedCentralPubMed
88.
Zurück zum Zitat Camm AJ, Lip GYH et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal (2012) 33, 2719–2747.PubMedCrossRef Camm AJ, Lip GYH et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal (2012) 33, 2719–2747.PubMedCrossRef
89.
Zurück zum Zitat Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.PubMedCrossRef Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.PubMedCrossRef
90.
Zurück zum Zitat Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators, Midland Research Practices Network (MidReC): Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370: 493–503.PubMedCrossRef Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators, Midland Research Practices Network (MidReC): Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370: 493–503.PubMedCrossRef
91.
Zurück zum Zitat Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–17.PubMedCrossRef Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–17.PubMedCrossRef
92.
Zurück zum Zitat Verhoef TI, Ragia G A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon, N Engl J Med 2013;369:2304–12PubMedCrossRef Verhoef TI, Ragia G A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon, N Engl J Med 2013;369:2304–12PubMedCrossRef
93.
94.
Zurück zum Zitat Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patientswith atrial fibrillation. N Engl J Med 2009; 361: 1139–51.PubMedCrossRef Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patientswith atrial fibrillation. N Engl J Med 2009; 361: 1139–51.PubMedCrossRef
95.
Zurück zum Zitat Granger CB, Alexander JH et al.; ARISTOTLE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.PubMedCrossRef Granger CB, Alexander JH et al.; ARISTOTLE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.PubMedCrossRef
96.
Zurück zum Zitat Patel MR, Mahaffey KW,et al; ROCKET AF Investigators. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.PubMedCrossRef Patel MR, Mahaffey KW,et al; ROCKET AF Investigators. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.PubMedCrossRef
97.
Zurück zum Zitat Endres M. et al.: Sekundärprophylaxe des ischämischen Insults. Leitlinie der DGN. 2012. AWMF-Registernummer: 030/133 Endres M. et al.: Sekundärprophylaxe des ischämischen Insults. Leitlinie der DGN. 2012. AWMF-Registernummer: 030/133
98.
Zurück zum Zitat Hohnloser SH, Crijns HJGM et al. for the ATHENA Investigators: Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. N Engl J Med 2009; 360:668–678.PubMedCrossRef Hohnloser SH, Crijns HJGM et al. for the ATHENA Investigators: Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. N Engl J Med 2009; 360:668–678.PubMedCrossRef
99.
Zurück zum Zitat Connolly SJ, Camm AJ,et al. PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365: 2268–2276.PubMedCrossRef Connolly SJ, Camm AJ,et al. PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365: 2268–2276.PubMedCrossRef
100.
Zurück zum Zitat Arbelo E, Brugada J, et al. on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. ESC-EURObservational research programme: the atrial fibrillation ablation pilot study, conducted by the European Heart Rhythm Association. Europace 2012;14:1094–1103.PubMedCrossRef Arbelo E, Brugada J, et al. on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. ESC-EURObservational research programme: the atrial fibrillation ablation pilot study, conducted by the European Heart Rhythm Association. Europace 2012;14:1094–1103.PubMedCrossRef
101.
Zurück zum Zitat Herm J, Fiebach JB, Koch L, Kopp UA, Kunze C, Wollboldt C, Brunecker P, Schultheiss HP, Schirdewan A, Endres M, Haeusler KG. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study Circ Arrhythm Electrophysiol. 2013 Oct;6(5):843–50.PubMedCrossRef Herm J, Fiebach JB, Koch L, Kopp UA, Kunze C, Wollboldt C, Brunecker P, Schultheiss HP, Schirdewan A, Endres M, Haeusler KG. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study Circ Arrhythm Electrophysiol. 2013 Oct;6(5):843–50.PubMedCrossRef
102.
Zurück zum Zitat (Meschia JF, Bushnell C et al. Guidelines fort he Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Associoation. Stroke. Published online October 28, 2014. (Meschia JF, Bushnell C et al. Guidelines fort he Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Associoation. Stroke. Published online October 28, 2014.
103.
Zurück zum Zitat De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286–2294.PubMedCrossRef De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286–2294.PubMedCrossRef
104.
Zurück zum Zitat Ridker PM et al: A randamized trial of low-dose aspirin in ther primary prevention of cardiovascular disease in woman. N Engl J Med. 2005; 352: 1293–1304.PubMedCrossRef Ridker PM et al: A randamized trial of low-dose aspirin in ther primary prevention of cardiovascular disease in woman. N Engl J Med. 2005; 352: 1293–1304.PubMedCrossRef
105.
Zurück zum Zitat Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796–1801.PubMedCrossRef Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796–1801.PubMedCrossRef
106.
Zurück zum Zitat Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–629.PubMedCrossRef Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–629.PubMedCrossRef
107.
Zurück zum Zitat Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.PubMedCrossRef Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.PubMedCrossRef
108.
Zurück zum Zitat Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedCentralPubMedCrossRef Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedCentralPubMedCrossRef
109.
Zurück zum Zitat Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56:956–965.PubMedCrossRef Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56:956–965.PubMedCrossRef
110.
Zurück zum Zitat Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–848.PubMedCrossRef Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–848.PubMedCrossRef
111.
Zurück zum Zitat Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009;18:482–490.PubMedCrossRef Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009;18:482–490.PubMedCrossRef
Metadaten
Titel
Primärprävention
Risikofaktoren für Schlaganfall und ihre therapeutische Beeinflussung
verfasst von
Dr. med. Burkhard Alber
Robert Müller
Prof. Dr. med. Gerhard F. Hamann
Publikationsdatum
06.02.2015
Verlag
Urban & Vogel
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 2/2015
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-015-0641-8

Weitere Artikel der Ausgabe 2/2015

DNP - Der Neurologe & Psychiater 2/2015 Zur Ausgabe